- Home
- TBN vs ABEO Comparison
TBN vs ABEO Comparison
Compare TBN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- ABEO
- Stock Information
- Founded
- TBN 2009
- ABEO 1974
- Country
- TBN Australia
- ABEO United States
- Employees
- TBN N/A
- ABEO N/A
- Industry
- TBN
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- TBN
- ABEO Health Care
- Exchange
- TBN NYSE
- ABEO Nasdaq
- Market Cap
- TBN 43.4B
- ABEO 256.9M
- IPO Year
- TBN 2024
- ABEO 1980
- Fundamental
- Price
- TBN $19.08
- ABEO $5.69
- Analyst Decision
- TBN Buy
- ABEO Strong Buy
- Analyst Count
- TBN 4
- ABEO 6
- Target Price
- TBN $34.75
- ABEO $18.00
- AVG Volume (30 Days)
- TBN 41.5K
- ABEO 1.1M
- Earning Date
- TBN 05-14-2025
- ABEO 08-11-2025
- Dividend Yield
- TBN N/A
- ABEO N/A
- EPS Growth
- TBN N/A
- ABEO N/A
- EPS
- TBN N/A
- ABEO N/A
- Revenue
- TBN N/A
- ABEO N/A
- Revenue This Year
- TBN N/A
- ABEO N/A
- Revenue Next Year
- TBN N/A
- ABEO $323.51
- P/E Ratio
- TBN N/A
- ABEO N/A
- Revenue Growth
- TBN N/A
- ABEO N/A
- 52 Week Low
- TBN $15.75
- ABEO $3.93
- 52 Week High
- TBN $34.50
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- ABEO 47.54
- Support Level
- TBN N/A
- ABEO $5.68
- Resistance Level
- TBN N/A
- ABEO $5.93
- Average True Range (ATR)
- TBN 0.00
- ABEO 0.26
- MACD
- TBN 0.00
- ABEO -0.01
- Stochastic Oscillator
- TBN 0.00
- ABEO 56.25
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.